Allarity Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • ALLR

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.90
  • (As of Wednesday Closing)

Allarity Therapeutics General Information

Description

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Contact Information

Formerly Known As
Medical Prognosis
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • East Tarpon Avenue
  • 123
  • Tarpon Springs, FL 34689
  • United States
+1 (401)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • East Tarpon Avenue
  • 123
  • Tarpon Springs, FL 34689
  • United States
+1 (401)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allarity Therapeutics Stock Performance

As of 18-Nov-2026, Allarity Therapeutics’s stock price is $0.90. Its current market cap is $14.3M with 16M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.90 $0.84 $0.77 - $1.84 $14.3M 16M 128K -$0.79

Allarity Therapeutics Financials Summary

As of 30-Jun-2026, Allarity Therapeutics has a trailing 12-month revenue of $345K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 22,209 1,837 (11,939) 4,754
Revenue 345 320 0 0
EBITDA (11,992) (11,847) (24,767) (11,305)
Net Income (12,334) (11,231) (24,515) (11,901)
Total Assets 32,115 18,258 22,650 11,862
Total Debt 22,286 1,400 1,350 1,300
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Allarity Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Allarity Therapeutics‘s full profile, request access.

Request a free trial

Allarity Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel ant
Drug Discovery
Tarpon Springs, FL
8 As of 2025

San Diego, CA
 

Princeton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allarity Therapeutics Competitors (12)

One of Allarity Therapeutics’s 12 competitors is Kura Oncology, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kura Oncology Formerly VC-backed San Diego, CA
Bristol-Myers Squibb Corporation Princeton, NJ
Sutro Biopharma Formerly VC-backed South San Francisco, CA
Prelude Therapeutics Formerly VC-backed Wilmington, DE
Lantern Pharma Formerly VC-backed Dallas, TX
You’re viewing 5 of 12 competitors. Get the full list »

Allarity Therapeutics Patents

Allarity Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026201368-A1 Methods for predicting responsiveness to daratumumab in a cancer subject Pending 20-Mar-2025
EP-4837974-A2 Methods for predicting responsiveness to daratumumab in a cancer subject Pending 20-Mar-2025
US-20260286445-A1 Methods for predicting responsiveness to daratumumab in a cancer subject Pending 20-Mar-2025
US-20240325396-A1 Methods for treating cancer Pending 17-Mar-2023
WO-2016046640-A2 Methods for predicting drug responsiveness Inactive 26-Sep-2014 C12Q1/6886
To view Allarity Therapeutics’s complete patent history, request access »

Allarity Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allarity Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Allarity Therapeutics‘s full profile, request access.

Request a free trial

Allarity Therapeutics Investments & Acquisitions (3)

Allarity Therapeutics’s most recent deal was a Merger/Acquisition with Oncology Venture US for . The deal was made on 13-Jul-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Oncology Venture US 13-Jul-2020 Merger/Acquisition Drug Discovery
Sass & Larsen (Dovitinib Program Based in Boston, Massachusetts) 08-Jun-2020 Corporate Asset Purchase Pharmaceuticals
Oncology Venture Sweden 24-Aug-2018 Merger/Acquisition Drug Discovery
To view Allarity Therapeutics’s complete investments and acquisitions history, request access »

Allarity Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Allarity Therapeutics’s complete esg history, request access »

Allarity Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Oncology Venture Sweden Horsholm, Denmark 2012

Allarity Therapeutics FAQs

  • When was Allarity Therapeutics founded?

    Allarity Therapeutics was founded in 2004.

  • Where is Allarity Therapeutics headquartered?

    Allarity Therapeutics is headquartered in Tarpon Springs, FL.

  • What is the size of Allarity Therapeutics?

    Allarity Therapeutics has 8 total employees.

  • What industry is Allarity Therapeutics in?

    Allarity Therapeutics’s primary industry is Drug Discovery.

  • Is Allarity Therapeutics a private or public company?

    Allarity Therapeutics is a Public company.

  • What is Allarity Therapeutics’s stock symbol?

    The ticker symbol for Allarity Therapeutics is ALLR.

  • What is the current stock price of Allarity Therapeutics?

    As of 18-Nov-2026 the stock price of Allarity Therapeutics is $0.90.

  • What is the current market cap of Allarity Therapeutics?

    The current market capitalization of Allarity Therapeutics is $14.3M.

  • What is Allarity Therapeutics’s current revenue?

    The trailing twelve month revenue for Allarity Therapeutics is $345K.

  • Who are Allarity Therapeutics’s competitors?

    Kura Oncology, Bristol-Myers Squibb, Sutro Biopharma, Prelude Therapeutics, and Lantern Pharma are some of the 12 competitors of Allarity Therapeutics.

  • What is Allarity Therapeutics’s annual earnings per share (EPS)?

    Allarity Therapeutics’s EPS for 12 months was -$0.79.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process